Destiny Pharma has published new data illustrating the efficacy of its anti-infective drug, XF-73, against MRSA and its superiority over one current standard of care in two skin infection studies.
Published in Infection & Drug Resistance, XR-73 was tested against methicillin-resistant Staphylococcus aureus (MRSA) in two, industry-standard, skin infection models and its efficacy compared to mupirocin, a leading topical antibiotic.
Mupirocin had little or no impact on resistant-MRSA strains in the skin infection model, even following 2 doses, whereas XF-73's potency was not impaired and was equally effective against the mupirocin-resistant MRSA strains, maintaining a >3 log10 reduction.
Bill Love, Destiny Pharma’s chief scientific officer, said: "This dataset is compelling and demonstrates clear and significant advantages for XF-73 over one of the world's leading topical antibiotics, mupirocin.
“It also provides a valuable additional read across of comparative activity against MRSA and mupirocin-resistant strains which are a growing cause of post-surgical infections and is therefore supportive of our XF-73 nasal gel product."
Debra Barker, Destiny’s interim chief executive officer, added: "The publication of these new data provides further evidence of the superiority of XF-73 over the leading standard of care and is highly relevant to our strategy to advance the product across a range of indications.”
Destiny Pharma has partnered with China Medical Systems to develop a dermal formulation of XR-73 as a treatment for superficial skin infections.